key: cord-0936744-h18vwyb2
authors: Eder, Michael; Strassl, Robert; Kläger, Johannes; Aigner, Christof; Thalhammer, Florian; Kikić, Željko
title: COVID-19: IgG seroconversion under intensive glucocorticoid treatment in a high-risk patient with minimal change disease
date: 2020-12-08
journal: Wien Klin Wochenschr
DOI: 10.1007/s00508-020-01776-w
sha: 50ce5ac03539e10e59b95bd5085733127ab1cc8b
doc_id: 936744
cord_uid: h18vwyb2

In this case report we present a rare case of a patient with multiple risk factors for severe coronavirus disease (COVID 19) in whom intensive glucocorticoid treatment due to incipient nephrotic syndrome coincided with SARS-CoV‑2 infection. Despite this high baseline risk profile and the use of glucocorticoids the patient developed only mild disease including IgG SARS-CoV‑2 seroconversion.

tine use of glucocorticoids due to prolonged viral shedding and reduced anti-viral type 1 interferon immune responses [3] . As suggested by Mehta et al. these concerns are countered by increasing evidence of COVID-19 subpopulations in which development of severe ARDS and multiorgan failure may be driven by virally induced secondary hyperinflammatory syndrome (SHS) and cytokine storm [1, 4] . Anecdotal reports in subjects without renal disease have suggested successful reversion of critical cases by nonselective (glucocorticoids, Intravenous immunoglobulin) or selective immunosuppression, i.e. interleukin 6 (IL-6) antagonism, mostly used as bail-out procedures. Prevention of severe COVID-19 and/or SHS at earlier disease stages through immunosuppression, however, may also be beneficial. So far, the evidence for prophylactic glucocorticoids treatment in nonsevere cases is limited by various uncertainties regarding optimal case selection, timing and dose of immunosuppression. Moreover, knowledge about immunocompromised patients with renal disease is derived mainly from case reports of renal transplant patients with varying clinical course but a not unsubstantial number of patients needed treatment at ICU units [5] . In this report we discuss a case of a patient with multiple risk factors for severe COVID-19 (obesity, renal disease, hypertension) in whom intensive glucocorticoid treatment due to incipient nephrotic syndrome coincided with SARS-CoV-2 infection. Despite this high baseline risk profile and the use of glucocorticoids the patient developed only mild disease including IgG SARS-CoV-2 seroconversion.

A 32-year-old male patient presented at our outpatient clinic with progressive fatigue, weight gain and edema. Physical examination showed an obese patient (163 kg) with lower extremity edema and mild hypertension (140/90 mm Hg). Laboratory findings (Table 1) confirmed a severe nephrotic syndrome (pro- Ethical standards The patient participating in this case report provided informed consent prior to publication.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

COVID-19: consider cytokine storm syndromes and immunosuppression

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?

Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon

Clinical predictors of mortality dueto COVID-19 basedon an analysis of data of 150 patients from Wuhan, China

Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?